Immune role of programmed death 1/programmed death-ligand pathway in Mycobacterium tuberculosis infection and prospects for host-directed therapy

doi:10.3877/cma.j.issn.1674-1358.2021.03.001

Abstract

Abstract:

The programmed death 1 (PD-1)/programmed death-ligand (PD-L) pathway had been a research hotspot in recent years, and its significant clinical benefit in patients with malignant tumors had provided new ideas for the treatment of patients with chronic infectious diseases. Cases of Mycobacteria tuberculosis (MTB) infection reactivity during PD-1 inhibitor treatment of malignant tumors have now been reported in the literature, which have shown a tendency to increase. Tuberculosis, a communicable disease caused by MTB, was a disease which cause the most number of deaths by a single pathogen. Latent MTB infection (LTBI) was pragmatically defined as infection with MTB. Latent tuberculosis infection could progress to active tuberculosis (ATB) under specific conditions. The epidemic situation of tuberculosis has brought severe challenges to the prevention and control of tuberculosis in China. This review discussed the immune role of PD-1/PD-L pathway in MTB infection and provides clues for in-depth understanding of MTB host immunity and exploring new tuberculosis host-directed therapy.

Key words: Programmed death 1/programmed death-ligand, Tuberculosis, Latent tuberculosis infection, T cell-mediated immunity, Host-directed therapy

Lifan Zhang, Zhengrong Yang, Xiaoqing Liu. Immune role of programmed death 1/programmed death-ligand pathway in Mycobacterium tuberculosis infection and prospects for host-directed therapy[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2021, 15(03): 145-148.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2021.03.001

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2021/V15/I03/145

Figures/Tables 1

References 36

[1]	World Health Organization. Global tuberculosis report 2016[EB/OL]. 2016. URL
[2]	李紫薇，杨东亮，刘嘉. 程序性死亡蛋白1靶向免疫治疗在慢性病毒性感染中的研究进展[J/CD]. 中华实验和临床感染病杂志(电子版),2020,14(5):361-366.
[3]	Rao M, Valentini D, Dodoo E, et al. Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm[J]. Int J Infect Dis,2017,56(3):221-228.
[4]	Byeon S, Cho JH, Jung HA, et al. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence[J]. Cancer Med,2020,9(7):2352-2362.
[5]	Anastasopoulou A, Ziogas DC, Samarkos M, et al. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations[J]. J Immunother Cancer,2019,7(1):239-252.
[6]	Barber DL, Sakai S, Kudchadkar RR, et al. Tuberculosis following PD-1 blockade for cancer immunotherapy[J]. Sci Transl Med,2019, 11(475):53-61.
[7]	Tsai CC, Chen JH, Wang YC, et al. Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment[J]. QJM,2019,112(1):41-42.
[8]	Takata S, Koh G, Han Y, et al. Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents[J]. J Infect Chemother,2019,25(1):54-58.
[9]	Picchi H, Mateus C, Chouaid C,et al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment[J]. Clin Microbiol Infect,2018,24(3):216-218.
[10]	Jensen KH, Persson G, Bondgaard AL,et al. Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer[J]. Acta Oncol,2018,57(8):1127-1128.
[11]	He W, Zhang X, Li W, et al. Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report[J]. Onco Targets Ther,2018,11(10):7423-7427.
[12]	Chu YC, Fang KC, Chen HC, et al. Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti-PD-1 treatment in a patient with advanced pulmonary adenocarcinoma[J]. J Thorac Oncol,2017,12(8):e111-e114.
[13]	Fujita K, Terashima T, Mio T. Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis[J]. J Thorac Oncol,2016,11(12):2238-2240.
[14]	Lee JJX, Chan A, Tang T. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin’s lymphoma[J]. Acta Oncologica,2016,55(4):519-520.
[15]	Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway[J]. N Engl J Med,2016,375(18):1767-1778.
[16]	Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells[J]. Proc Natl Acad Sci USA,2003,100(9):5336-5341.
[17]	Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas[J]. Nat Rev Clin Oncol,2017,14(4): 203-220.
[18]	Day CL, Abrahams DA, Bunjun R, et al. PD-1 expression on Mycobacterium tuberculosis-specific CD4⁺ T cells is associated with bacterial load in human tuberculosis[J]. Front Immunol,2018,9(8): 1995-2013.
[19]	Shen L, Shi H, Gao Y, et al. The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis[J]. Tuberculosis (Edinb),2016,101(6):146-150.
[20]	Cao S, Li J, Lu J, et al. Mycobacterium tuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway[J]. Cell Death Dis,2019,10(2):44-56.
[21]	Mahon RN, Hafner R. Applying precision medicine and immunotherapy advances from oncology to host-directed therapies for infectious diseases[J]. Front Immunol,2017,8(6):688-794.
[22]	Singh A, Dey AB, Mohan A, et al. Programmed death-1 receptor suppresses gamma-IFN producing NKT cells in human tuberculosis[J]. Tuberculosis (Edinb),2014,94(3):197-206.
[23]	Zumla A, Rao M, Dodoo E, et al. Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis[J]. BMC Med,2016,14(6):89-101.
[24]	Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis[J]. Nat Rev Immunol,2015,15(4):255-263.
[25]	Reungwetwattana T, Adjei AA. Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis[J]. J Thorac Oncol,2016,11(12):2048-2050.
[26]	Kaufmann SH. How can immunology contribute to the control of tuberculosis?[J]. Nat Rev Immunol,2001,1(1):20-30.
[27]	Lazar-Molnar E, Chen B, Sweeney KA, et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis[J]. Proc Natl Acad Sci USA,2010,107(30):13402-13407.
[28]	Barber DL, Mayer-Barber KD, Feng CG, et al. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition[J]. J Immunol,2011,186(3):1598-1607.
[29]	Sakai S, Kauffman KD, Sallin MA, et al. CD4 T cell-derived IFN-gamma plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease[J]. PLoS Pathog,2016,12(5):e1005667.
[30]	孙萌萌，秦川，唐军, 等. 阻断巨噬细胞介导的PD1/PD-L1通路对小鼠结核复发的抑制作用[J]. 中国比较医学杂志,2018,28(4):50-58.
[31]	Shen L, Gao Y, Liu Y, et al. PD-1/PD-L pathway inhibits M.tb-specific CD4(+) T-cell functions and phagocytosis of macrophages in active tuberculosis[J]. Sci Rep,2016,6(1):38362-38371.
[32]	Singh A, Mohan A, Dey AB,et al. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis[J]. J Infect Dis,2013,208(4):603-615. URL
[33]	占玲俊，唐军，秦川. PD-1: PD-L1/PD-L2通路在结核感染中的免疫作用[J]. 中国比较医学杂志,2015,25(7):74-76.
[34]	Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J]. Nat Immunol,2001,2(3): 261-268.
[35]	Zhang Y, Chung Y, Bishop C, et al. Regulation of T cell activation and tolerance by PDL2[J]. Proc Natl Acad Sci USA,2006,103(31):11695-11700.
[36]	Karunarathne DS, Horne-Debets JM, Huang JX, et al. Programmed death-1 ligand 2-mediated regulation of the PD-L1 to PD-1 axis is essential for establishing CD4(+) T cell immunity[J]. Immunity, 2016,45(2):333-345.

参考文献	发表年份	性别	年龄	种族	肿瘤	药物	药物类型	确诊结核时间	诊断	结核部位	抗结核治疗方案	抗结核治疗结局
Byeon S等^[4]	2020	女	57	亚洲	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗22周期	BAL	肺	药物不详，共6个月	不详
		男	61	亚洲	转移性非小细胞肺癌	帕博利珠单抗	PD-1抑制剂	治疗2周期	不详	肺	药物不详，共6个月	不详
		女	84	亚洲	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗4周期	不详	肺	不详	不详
Anastasopoulou A等^[5]	2019	女	76	高加索	转移性黑色素瘤	纳武利尤单抗	PD-1抑制剂	治疗14周期	BAL、PCR	肺	HRZE（1周）	死亡
Barber DL等^[6]	2019	男	59	亚洲	转移性鼻咽癌	纳武利尤单抗	PD-1抑制剂	治疗3周期	组织学、BAL、痰PCR	播散性	1HRZE	死亡
Barber DL等^[6]	2019	男	83	高加索	默克尔细胞瘤	帕博利珠单抗	PD-1抑制剂	治疗11周期	组织学	肺	HRZE→RO共9月	治愈
Tsai CC等^[7]	2019	男	49	亚洲	硬腭鳞状细胞癌	纳武利尤单抗	PD-1抑制剂	治疗6周期	痰培养、抗酸染色	肺	药物不详，共5个月	死亡
Takata S等^[8]	2019	男	75	亚洲	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗15周期	痰涂片抗酸染色、PCR	肺	HRZE 10 d→HEO（不详）→7HR	治愈
Picchi H等^[9]	2018	男	50	高加索	转移性黑色素瘤	帕博利珠单抗	PD-1抑制剂	治疗4周期	组织学、PPD	胸膜	HRZE （时间不详）	治愈
Picchi H等^[9]	2018	男	64	高加索	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗2周期	组织学、骨培养、PCR	骨	HRZE（时间不详）	死亡
Jensen KH等^[10]	2018	男	56	高加索	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗12周期	组织学、PCR	肺	不详	不详
He W等^[11]	2018	女	65	亚洲	转移性黑色素瘤	帕博利珠单抗	PD-1抑制剂	治疗10周期	Xpert、BAL培养	肺	2HRZE→4SEO	治愈
Chu YC等^[12]	2017	男	59	亚洲	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗3周期	组织学、心包液培养	心包	不详	治愈
Fujita K等^[13]	2016	男	72	亚洲	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗8周期	BAL培养、PCR，IGRA	肺	不详	不详
Lee JJ等^[14]	2016	男	87	亚洲	霍奇金淋巴瘤	纳武利尤单抗	PD-1抑制剂	治疗5周期	痰培养	肺	HRE（时间不详）	治愈

参考文献	发表年份	性别	年龄	种族	肿瘤	药物	药物类型	确诊结核时间	诊断	结核部位	抗结核治疗方案	抗结核治疗结局
Byeon S等^[4]	2020	女	57	亚洲	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗22周期	BAL	肺	药物不详，共6个月	不详
		男	61	亚洲	转移性非小细胞肺癌	帕博利珠单抗	PD-1抑制剂	治疗2周期	不详	肺	药物不详，共6个月	不详
		女	84	亚洲	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗4周期	不详	肺	不详	不详
Anastasopoulou A等^[5]	2019	女	76	高加索	转移性黑色素瘤	纳武利尤单抗	PD-1抑制剂	治疗14周期	BAL、PCR	肺	HRZE（1周）	死亡
Barber DL等^[6]	2019	男	59	亚洲	转移性鼻咽癌	纳武利尤单抗	PD-1抑制剂	治疗3周期	组织学、BAL、痰PCR	播散性	1HRZE	死亡
Barber DL等^[6]	2019	男	83	高加索	默克尔细胞瘤	帕博利珠单抗	PD-1抑制剂	治疗11周期	组织学	肺	HRZE→RO共9月	治愈
Tsai CC等^[7]	2019	男	49	亚洲	硬腭鳞状细胞癌	纳武利尤单抗	PD-1抑制剂	治疗6周期	痰培养、抗酸染色	肺	药物不详，共5个月	死亡
Takata S等^[8]	2019	男	75	亚洲	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗15周期	痰涂片抗酸染色、PCR	肺	HRZE 10 d→HEO（不详）→7HR	治愈
Picchi H等^[9]	2018	男	50	高加索	转移性黑色素瘤	帕博利珠单抗	PD-1抑制剂	治疗4周期	组织学、PPD	胸膜	HRZE （时间不详）	治愈
Picchi H等^[9]	2018	男	64	高加索	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗2周期	组织学、骨培养、PCR	骨	HRZE（时间不详）	死亡
Jensen KH等^[10]	2018	男	56	高加索	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗12周期	组织学、PCR	肺	不详	不详
He W等^[11]	2018	女	65	亚洲	转移性黑色素瘤	帕博利珠单抗	PD-1抑制剂	治疗10周期	Xpert、BAL培养	肺	2HRZE→4SEO	治愈
Chu YC等^[12]	2017	男	59	亚洲	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗3周期	组织学、心包液培养	心包	不详	治愈
Fujita K等^[13]	2016	男	72	亚洲	转移性非小细胞肺癌	纳武利尤单抗	PD-1抑制剂	治疗8周期	BAL培养、PCR，IGRA	肺	不详	不详
Lee JJ等^[14]	2016	男	87	亚洲	霍奇金淋巴瘤	纳武利尤单抗	PD-1抑制剂	治疗5周期	痰培养	肺	HRE（时间不详）	治愈

Please choose a citation manager

Content to export